Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

[1]  A. Zhu,et al.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.

[2]  K. Shitara,et al.  Development of circulating tumour DNA analysis for gastrointestinal cancers , 2020, ESMO Open.

[3]  Harpreet Wasan,et al.  Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2019, The New England journal of medicine.

[4]  Leah M Chase,et al.  Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma , 2019, Clinical Cancer Research.

[5]  Catalin C. Barbacioru,et al.  Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel , 2019, Clinical Cancer Research.

[6]  Jeffrey W. Clark,et al.  Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers , 2019, Nature Medicine.

[7]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[8]  Crispin J. Miller,et al.  Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study , 2019, Nature Medicine.

[9]  V. Papadimitrakopoulou,et al.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.

[10]  Sharyn I. Katz,et al.  Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.

[11]  A. Balmain,et al.  A model for RAS mutation patterns in cancers: finding the sweet spot , 2018, Nature Reviews Cancer.

[12]  T. Yoshino,et al.  Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. , 2018, The oncologist.

[13]  E. Helman,et al.  Abstract 4272: A novel approach to differentiation of somatic vs. germline variants in liquid biopsies using a betabinomial model , 2018, Bioinformatics and Systems Biology.

[14]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[15]  John L Marshall,et al.  Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers , 2018, Molecular Cancer Research.

[16]  I. Tsigelny,et al.  Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. , 2018, Cancer discovery.

[17]  F. Abtin,et al.  Non–small cell lung cancer clinical trials requiring biopsies with biomarker‐specific results for enrollment provide unique challenges , 2017, Cancer.

[18]  Menghong Sun,et al.  Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations , 2017, Nature Communications.

[19]  C. Paweletz,et al.  Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients , 2017, Clinical Cancer Research.

[20]  J. Shay,et al.  Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer , 2017, Journal of the National Cancer Institute.

[21]  E. Friedman,et al.  Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. , 2017, The oncologist.

[22]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[23]  H. Bando.  The current status and problems confronted in delivering precision medicine in Japan and Europe. , 2017, Current problems in cancer.

[24]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[25]  Lisa M McShane,et al.  Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. , 2017, The Journal of molecular diagnostics : JMD.

[26]  Benjamin J. Raphael,et al.  Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.

[27]  Anil Vachani,et al.  Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA , 2016, Clinical Cancer Research.

[28]  R. Salgia,et al.  Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer , 2016, Oncotarget.

[29]  Ann M. Bailey,et al.  Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[31]  F. Shepherd,et al.  Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.